No retraction, correction or concern found when last checked on Oct 27, 2026.

How can nanotechnology help to combat COVID-19? Opportunities and urgent need

Estefânia V. R. Campos, Anderson E. S. Pereira, Jhones Luiz de Oliveira and 4 more

Journal of Nanobiotechnology · 2020 · Review · CC BY

Abstract

Incidents of viral outbreaks have increased at an alarming rate over the past decades. The most recent human coronavirus known as COVID-19 (SARS-CoV-2) has already spread around the world and shown R 0 values from 2.2 to 2.68. However, the ratio between mortality and number of infections seems to be lower in this case in comparison to other human coronaviruses (such as severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV)). These outbreaks have tested the limits of healthcare systems and have posed serious questions about management using conventional therapies and diagnostic tools. In this regard, the use of nanotechnology offers new opportunities for the development of novel strategies in terms of prevention, diagnosis and treatment of COVID-19 and other viral infections. In this review, we discuss the use of nanotechnology for COVID-19 virus management by the development of nano-based materials, such as disinfectants, personal protective equipment, diagnostic systems and nanocarrier systems, for treatments and vaccine development, as well as the challenges and drawbacks that need addressing.

References 208

1.
Dhama K, Pawaiya RVS, Chakrabort S, Tiwari R, Saminathan M, Verma AK. Coronavirus infection in equines: a review. Asian J Anim Vet Adv. 2014;9:164-176.
Not in our library
2.
Coronavirus envelope protein: current knowledge · 2019
No notice
3.
A pneumonia outbreak associated with a new coronavirus of probable bat origin · 2020
No notice
4.
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199-1207.
Not in our library10.1056/nejmoa2001316
5.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-513.
Not in our library10.1016/s0140-6736(20)30211-7
6.
Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020;27:taaa021.
Not in our library10.1093/jtm/taaa021
7.
Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Bio Medica Atenei Parmensis. 2020;91:157-160.
Not in our library10.23750/abm.v91i1.9397
8.
Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181-192.
Not in our library10.1038/s41579-018-0118-9
9.
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565-574.
Not in our library10.1016/s0140-6736(20)30251-8
10.
A new coronavirus associated with human respiratory disease in China · 2020
Corrected
11.
Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94:e00127-20.
Not in our library10.1128/jvi.00127-20
12.
Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. Mol Biol. 2020.
Not in our library10.1101/2020.01.31.929042
13.
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260-1263.
Not in our library10.1126/science.abb2507
14.
Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5:562-569.
Not in our library10.1038/s41564-020-0688-y
15.
A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) · 2020
No notice
16.
Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet. 2020;395:e35-e36.
Not in our library10.1016/s0140-6736(20)30305-6
17.
Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan · 2020
Corrected
18.
Vellingiri B, Jayaramayya K, Iyer M, Narayanasamy A, Govindasamy V, Giridharan B, et al. COVID-19: a promising cure for the global panic. Sci Total Environ. 2020;725:138277.
Not in our library10.1016/j.scitotenv.2020.138277
19.
Hui L, Yeming W, Jiuyang X, Bin C. Potential antiviral therapeutics for 2019 Novel Coronavirus. Chin J Tuberc Respir Dis. 2020;43:170-172.
Not in our library10.3760/cma.j.issn.1001-0939.2020.03.004
20.
Zhang J, Zhou L, Yang Y, Peng W, Wang W, Chen X. Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics. Lancet Respir Med. 2020;8:e11-e12.
Not in our library10.1016/s2213-2600(20)30071-0
21.
Xia B, Kang X. Activation and maturation of SARS-CoV main protease. Protein Cell. 2011;2:282-290.
Not in our library10.1007/s13238-011-1034-1
22.
Kang S, Peng W, Zhu Y, Lu S, Zhou M, Lin W, et al. Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment. Int J Antimicrob Agents. 2020;55:105950.
Not in our library10.1016/j.ijantimicag.2020.105950
23.
Strasfeld L, Chou S. Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin N Am. 2010;24:413-437.
Not in our library10.1016/j.idc.2010.01.001
24.
Jackman JA, Lee J, Cho N-J. Nanomedicine for infectious disease applications: innovation towards broad-spectrum treatment of viral infections. Small. 2016;12:1133-1139.
Not in our library10.1002/smll.201500854
25.
Chen W-H, Strych U, Hotez PJ, Bottazzi ME. The SARS-CoV-2 vaccine pipeline: an overview. Curr Trop Med Rep. 2020;7:61-64.
Not in our library10.1007/s40475-020-00201-6
26.
Revuelta-Herrero JL, Chamorro-de-Vega E, Rodríguez-González CG, Alonso R, Herranz-Alonso A, Sanjurjo-Sáez M. Effectiveness, safety, and costs of a treatment switch to dolutegravir plus rilpivirine dual therapy in treatment-experienced HIV patients. Ann Pharmacother. 2018;52:11-18.
Not in our library10.1177/1060028017728294
27.
Mohammadi Pour P, Fakhri S, Asgary S, Farzaei MH, Echeverría J. The signaling pathways, and therapeutic targets of antiviral agents: focusing on the antiviral approaches and clinical perspectives of anthocyanins in the management of viral diseases. Front Pharmacol. 2019;10:1207.
Not in our library10.3389/fphar.2019.01207
28.
Lembo D, Donalisio M, Civra A, Argenziano M, Cavalli R. Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections. Expert Opin Drug Deliv. 2018;15:93-114.
Not in our library10.1080/17425247.2017.1360863
29.
Singh L, Kruger HG, Maguire GEM, Govender T, Parboosing R. The role of nanotechnology in the treatment of viral infections. Ther Adv Infect Dis. 2017;4:105-131.
Not in our library10.1177/2049936117713593
30.
Szunerits S, Barras A, Khanal M, Pagneux Q, Boukherroub R. Nanostructures for the inhibition of viral infections. Molecules. 2015;20:14051-14081.
Not in our library10.3390/molecules200814051
31.
Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics · 2017
Corrected
32.
Nano based drug delivery systems: recent developments and future prospects · 2018
No notice
33.
Nanomedicine: Principles, Properties, and Regulatory Issues · 2018
No notice
34.
Fornaguera C, García-Celma MJ. Personalized nanomedicine: a revolution at the nanoscale. J Personal Med. 2017;7:12-20.
Not in our library10.3390/jpm7040012
35.
Ben-Shabat S, Yarmolinsky L, Porat D, Dahan A. Antiviral effect of phytochemicals from medicinal plants: applications and drug delivery strategies. Drug Deliv Transl Res. 2020;10:354-367.
Not in our library10.1007/s13346-019-00691-6
36.
Nanoformulations of curcumin: an emerging paradigm for improved remedial application · 2017
No notice
37.
Anti-infective Properties of the Golden Spice Curcumin · 2019
No notice
38.
Watkins R, Wu L, Zhang C, Davis RM, Xu B. Natural product-based nanomedicine: recent advances and issues. Int J Nanomedicine. 2015;10:6055-6074.
Not in our library10.2147/ijn.s92162
39.
Mokhtarzadeh A, Eivazzadeh-Keihan R, Pashazadeh P, Hejazi M, Gharaatifar N, Hasanzadeh M, et al. Nanomaterial-based biosensors for detection of pathogenic virus. Trends Anal Chem. 2017;97:445-457.
Not in our library10.1016/j.trac.2017.10.005
40.
Kizek R, Krejcova L, Michalek P, Merlos Rodrigo M, Heger Z, Krizkova S, et al. Nanoscale virus biosensors: state of the art. NDD. 2015;4:47-66.
Not in our library
41.
Nanoparticle-Based Vaccines Against Respiratory Viruses · 2019
No notice
42.
Vijayan V, Mohapatra A, Uthaman S, Park IK. Recent advances in nanovaccines using biomimetic immunomodulatory materials. Pharmaceutics. 2019;11:534.
Not in our library10.3390/pharmaceutics11100534
43.
Luo R, Fang L, Jin H, Wang D, An K, Xu N, et al. Label-free quantitative phosphoproteomic analysis reveals differentially regulated proteins and pathway in PRRSV-Infected Pulmonary Alveolar Macrophages. J Proteome Res. 2014;13:1270-1280.
Not in our library10.1021/pr400852d
44.
Pan H, Zhang P, Gao D, Zhang Y, Li P, Liu L, et al. Noninvasive visualization of respiratory viral infection using bioorthogonal conjugated near-infrared-emitting quantum dots. ACS Nano. 2014;8:5468-5477.
Not in our library10.1021/nn501028b
45.
Zhang Y, Ke X, Zheng Z, Zhang C, Zhang Z, Zhang F, et al. Encapsulating quantum dots into enveloped virus in living cells for tracking virus infection. ACS Nano. 2013;7:3896-3904.
Not in our library10.1021/nn305189n
46.
Kramer A, Assadian O. Survival of microorganisms on inanimate surfaces. In: Use of biocidal surfaces for reduction of healthcare acquired infections. Springer International Publishing AG; 2014. p. 7–26.
Not in our library
47.
Human Coronaviruses: Insights into Environmental Resistance and Its Influence on the Development of New Antiseptic Strategies · 2012
No notice
48.
Lee W-S, Hsieh T-C, Shiau JC, Ou T-Y, Chen F-L, Liu Y-H, et al. Bio-Kil, a nano-based disinfectant, reduces environmental bacterial burden and multidrug-resistant organisms in intensive care units. J Microbiol Immunol Infect. 2017;50:737-746.
Not in our library10.1016/j.jmii.2016.04.008
49.
Karunanayake LI, Waniganayake YC, Gunawardena KDN, Padmaraja SAD, Peter D, Jayasekera R, et al. Use of silicon nanoparticle surface coating in infection control: experience in a tropical healthcare setting. Infect Dis Health. 2019;24:201-207.
Not in our library10.1016/j.idh.2019.06.006
50.
Ortí-Lucas RM, Muñoz-Miguel J. Effectiveness of surface coatings containing silver ions in bacterial decontamination in a recovery unit. Antimicrob Resist Infect Control. 2017;6:61.
Not in our library10.1186/s13756-017-0217-9
51.
Si Y, Zhang Z, Wu W, Fu Q, Huang K, Nitin N, et al. Daylight-driven rechargeable antibacterial and antiviral nanofibrous membranes for bioprotective applications. Sci Adv. 2018;4:eaar5931.
Not in our library10.1126/sciadv.aar5931
52.
Herron JBT, Hay-David AGC, Gilliam AD, Brennan PA. Personal protective equipment and Covid 19—a risk to healthcare staff? Br J Oral Maxillofac Surg. 2020;58(5):500-502.
Not in our library10.1016/j.bjoms.2020.04.015
53.
van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382:1564-1567.
Not in our library10.1056/nejmc2004973
54.
Kampf G. Potential role of inanimate surfaces for the spread of coronaviruses and their inactivation with disinfectant agents. Infect Prev Pract. 2020;2:100044.
Not in our library10.1016/j.infpip.2020.100044
55.
Cleaning and Disinfectant Chemical Exposures and Temporal Associations with COVID-19 — National Poison Data System, United States, January 1, 2020–March 31, 2020 · 2020
No notice
56.
Kapoor A, Saha R. Hand washing agents and surface disinfectants in times of Coronavirus (COVID-19) outbreak. Indian J Community Health. 2020;32:225-227.
Not in our library
57.
Huang H, Fan C, Li M, Nie H-L, Wang F-B, Wang H, et al. COVID-19: a call for physical scientists and engineers. ACS Nano. 2020;14(4):3747-3754.
Not in our library10.1021/acsnano.0c02618
58.
Querido MM, Aguiar L, Neves P, Pereira CC, Teixeira JP. Self-disinfecting surfaces and infection control. Colloids Surf B Biointerfaces. 2019;178:8-21.
Not in our library10.1016/j.colsurfb.2019.02.009
59.
Geyer F, D’Acunzi M, Sharifi-Aghili A, Saal A, Gao N, Kaltbeitzel A, et al. When and how self-cleaning of superhydrophobic surfaces works. Sci Adv. 2020;6:eaaw9727.
Not in our library10.1126/sciadv.aaw9727
60.
Dalawai SP, Saad Aly MA, Latthe SS, Xing R, Sutar RS, Nagappan S, et al. Recent advances in durability of superhydrophobic self-cleaning technology: a critical review. Prog Org Coat. 2020;138:105381.
Not in our library
61.
Dyshlyuk L, Babich O, Ivanova S, Vasilchenco N, Prosekov A, Sukhikh S. Suspensions of metal nanoparticles as a basis for protection of internal surfaces of building structures from biodegradation. Case Stud Constr Mater. 2020;12:e00319.
Not in our library
62.
Rai M, Deshmukh SD, Ingle AP, Gupta IR, Galdiero M, Galdiero S. Metal nanoparticles: the protective nanoshield against virus infection. Crit Rev Microbiol. 2016;42:46-56.
Not in our library10.3109/1040841x.2013.879849
63.
Vaze N, Pyrgiotakis G, McDevitt J, Mena L, Melo A, Bedugnis A, et al. Inactivation of common hospital acquired pathogens on surfaces and in air utilizing engineered water nanostructures (EWNS) based nano-sanitizers. Nanomed Nanotechnol Biol Med. 2019;18:234-242.
Not in our library10.1016/j.nano.2019.03.003
64.
StatNano. Coronavirus: nanotech surface sanitizes milan with nanomaterials remaining self-sterilized for years | STATNANO. 2020. https://statnano.com//news/67531/Coronavirus-Nanotech-Surface-Sanitizes-Milan-with-Nanomaterials-Remaining-Self-sterilized-for-Years. Accessed 28 Apr 2020.
Not in our library
65.
StatNano. Mineral nanocrystal-based coating activated by light kills coronavirus | STATNANO. 2020. https://statnano.com/news/67583/Mineral-Nanocrystal-based-Coating-Activated-by-Light-Kills-Coronavirus. Accessed 7 Aug 2020.
Not in our library
66.
Chan WCW. Nano research for COVID-19. ACS Nano. 2020;14:3719-3720.
Not in our library10.1021/acsnano.0c02540
67.
Abo-zeid Y, Urbanowicz RA, Thomson BJ, Irving WL, Tarr AW, Garnett MC. Enhanced nanoparticle uptake into virus infected cells: could nanoparticles be useful in antiviral therapy? Int J Pharm. 2018;547:572-581.
Not in our library10.1016/j.ijpharm.2018.06.027
68.
Li Y, Lin Z, Zhao M, Xu T, Wang C, Hua L, et al. Silver nanoparticle based codelivery of oseltamivir to inhibit the activity of the H1N1 Influenza Virus through ROS-mediated signaling pathways. ACS Appl Mater Interfaces. 2016;8:24385-24393.
Not in our library10.1021/acsami.6b06613
69.
Kim J, Yeom M, Lee T, Kim H-O, Na W, Kang A, et al. Porous gold nanoparticles for attenuating infectivity of influenza A virus. J Nanobiotechnol. 2020;18:54.
Not in our library10.1186/s12951-020-00611-8
70.
Sun B, Zhang M, He Z, Zheng L, Shen J, Ni Y. Towards greener and more sustainable cellulose-based hand sanitizer products. JB&B. 2017;2:56-60.
Not in our library
71.
Park S, Ko Y-S, Lee SJ, Lee C, Woo K, Ko G. Inactivation of influenza A virus via exposure to silver nanoparticle-decorated silica hybrid composites. Environ Sci Pollut Res. 2018;25:27021-27030.
Not in our library10.1007/s11356-018-2620-z
72.
Neal J, Sirsat S. Titanium dioxide nanoparticles as an environmental sanitizing agent. J Microb Biochem Technol. 2015;07:61-64.
Not in our library
73.
Joost U, Juganson K, Visnapuu M, Mortimer M, Kahru A, Nõmmiste E, et al. Photocatalytic antibacterial activity of nano-TiO2 (anatase)-based thin films: effects on Escherichia coli cells and fatty acids. J Photochem Photobiol B. 2015;142:178-185.
Not in our library10.1016/j.jphotobiol.2014.12.010
74.
Wei G, Nguyen D, Reghu S, Li J, Chua C, Ishida Y, et al. Fast-bactericidal effect of polyion complex nanoparticles on gram-negative bacteria. ACS Appl Nano Mater. 2020;3:2654-2664.
Not in our library
75.
Vandhana T, Clement Lourduraj AJ. Biogenic synthesis of Mn-Ag co-doped FeO (Fe1-2xMnxAgx) nanoparticles: as an effective disinfectant and anticancer agent. Inorg Chem Commun. 2020;112:107712.
Not in our library
76.
SZALAY SFD. Skin sanitizer compositions comprising alcohol based emulsion. 2013. https://patents.google.com/patent/EP2654670A2/en. Accessed 26 Apr 2020.
Not in our library
77.
Hu K, Liu H. Preparation method and application of essential oil and plga (poly(lactic-co-glycolic acid)) compounded shell-core structure nanoparticles. CN109568180A. 2019. https://worldwide.espacenet.com/patent/search/family/065924361/publication/CN109568180A?q=CN109568180A&queryLang=en%3Ade%3Afr.
Not in our library
78.
Chiattello ML, Oman M. Polymer-based antimicrobial compositions and methods of use thereof. EP3493676A1. 2019. https://worldwide.espacenet.com/patent/search/family/061011855/publication/EP3493676A1?q=EP3493676A1&queryLang=en%3Ade%3Afr.
Not in our library
79.
Jones S, Stellacci F. Virucidal compounds and uses thereof. EP3487508A1. 2019. https://worldwide.espacenet.com/patent/search/family/056550084/publication/EP3487508A1?q=EP3487508A1&queryLang=en%3Ade%3Afr.
Not in our library
80.
Shivdas HP, Vitthal MR. Environment-friendly silver nanocomposite and method for same. IN1426/MUM/2014, 2015. https://www.quickcompany.in/patents/environment-friendly-silver-nanocomposite-and-method-for-same.
Not in our library
81.
GONDAL MA, Dastageer MA, Khalil AB, Siddique RG, Baig U. Method of forming a photocatalyst and disinfecting a fluid. 2019 https://patents.google.com/patent/US10421672B2/en. Accessed 26 Apr 2020.
Not in our library
82.
Grossman C, Ngo M, Wysocki R. Composition and method to form a self decontaminating surface. 2019. https://patents.google.com/patent/US10421870B2/en. Accessed 26 Apr 2020.
Not in our library
83.
Gutiérrez GL. Nanoparticulate titanium dioxide nanomaterial modified with functional groups and with citric extracts adsorbed on the surface, for the removal of a wide range of microorganisms. 2019. https://patents.google.com/patent/US10342840B2/en. Accessed 19 Apr 2020.
Not in our library
84.
Rösch A, Schaefer C. Metal Dispersion with Increased Stability. EP3368204A1. 2018. https://worldwide.espacenet.com/patent/search/family/057130386/publication/EP3368204A1?q=EP3368204A1&queryLang=en%3Ade%3Afr.
Not in our library
85.
Liu Y, Sun W. Preparation method of nanometer silver/quaternary ammonium salt composite sanitizer. CN108391673A, 2018. https://worldwide.espacenet.com/patent/search/family/063091462/publication/CN108391673A?q=CN108391673A&queryLang=en%3Ade%3Afr.
Not in our library
86.
CDC. Coronavirus disease 2019 (COVID-19)—transmission. Centers for Disease Control and Prevention. 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/how-covid-spreads.html. Accessed 11 Aug 2020.
Not in our library
87.
Conlon M. A facemask having one or more nanofiber layers. 2014. https://patents.google.com/patent/WO2014143039A1/en. Accessed 27 Apr 2020.
Not in our library
88.
Lustenberger F. Nanofiber filtering material for disposable/reusable respirators. 2016. https://patents.google.com/patent/US9446547B2/en. Accessed 27 Apr 2020.
Not in our library
89.
Ren G, Oxford PJS, Reip PW, Lambkin-Williams R, Mann A. Anti-viral formulations nanomaterials and nanoparticles. 2013. https://patents.google.com/patent/US20130091611/de. Accessed 27 Apr 2020.
Not in our library
90.
Yetisen AK, Qu H, Manbachi A, Butt H, Dokmeci MR, Hinestroza JP, et al. Nanotechnology in textiles. ACS Nano. 2016;10:3042-3068.
Not in our library10.1021/acsnano.5b08176
91.
Spagnol C, Fragal EH, Pereira AGB, Nakamura CV, Muniz EC, Follmann HDM, et al. Cellulose nanowhiskers decorated with silver nanoparticles as an additive to antibacterial polymers membranes fabricated by electrospinning. J Colloid Interface Sci. 2018;531:705-715.
Not in our library10.1016/j.jcis.2018.07.096
92.
Mansi A, Boccuni F, Iavicoli S. Nanomaterials as a new opportunity for protecting workers from biological risk. Ind Health. 2019;57:668-675.
Not in our library10.2486/indhealth.2018-0197
93.
El-Nahhal IM, Salem J, Anbar R, Kodeh FS, Elmanama A. Preparation and antimicrobial activity of ZnO-NPs coated cotton/starch and their functionalized ZnO-Ag/cotton and Zn(II) curcumin/cotton materials. Sci Rep. 2020;10:5410.
Not in our library10.1038/s41598-020-61306-6
94.
Srinivas AD, Peng C, Mittal AC, Agarwal P. Surfaces having particles and related methods. 2014. https://patents.google.com/patent/US20140041905A1/en. Accessed 27 Apr 2020.
Not in our library
95.
Elston DM. Occupational skin disease among health care workers during the coronavirus (COVID-19) epidemic. J Am Acad Dermatol. 2020;82:1085-1086.
Not in our library10.1016/j.jaad.2020.03.012
96.
Kanovsky M. Antimicrobial fabric materials for use in safety masks and personal protection clothing. 2016. https://patents.google.com/patent/WO2016125173A1/no. Accessed 27 Apr 2020.
Not in our library
97.
Clement S. Kupfer(II)enthaltende Formmasse aus Polyester, ihre Herstellung und Verwendung. 2008. https://patents.google.com/patent/DE102007003649A1/de. Accessed 10 Aug 2020.
Not in our library
98.
ФУДЖИMOPИ И, ДЖИКИXИPA И, CATO T, ФУКУИ Й, HAКAЯMA Ц. Virus inactivating cloth. 2015. https://patents.google.com/patent/RU2550922C2/en. Accessed 27 Apr 2020.
Not in our library
99.
Deshmukh SP, Patil SM, Mullani SB, Delekar SD. Silver nanoparticles as an effective disinfectant: a review. Mater Sci Eng C. 2019;97:954-965.
Not in our library10.1016/j.msec.2018.12.102
100.
Amigoni S, Josse D, Devers T, Zenerino A, Guittard F, de Givenchy ET, et al. Polymerised cerium oxide nanoparticles in an active or bioactive network, protective topical treatments, methods for preparation thereof and uses thereof. 2018. https://patents.google.com/patent/US10155869B2/en. Accessed 27 Apr 2020.
Not in our library
101.
Ballard RL, Anneaux BL, Manasco JL, Garner DP, Hao P. Electrospun porous media. 2013. https://patents.google.com/patent/US20130197664A1/en. Accessed 27 Apr 2020.
Not in our library
102.
고군호, 박종철. Face mask having nano fiber layer. 2012. https://patents.google.com/patent/KR101130788B1/en. Accessed 23 June 2020.
Not in our library
103.
Kwak JH. Antiviral treatment method, antiviral filter, and mask having same. 2019. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019160261. Accessed 23 June 2020.
Not in our library
104.
Udugama B, Kadhiresan P, Kozlowski HN, Malekjahani A, Osborne M, Li VYC, et al. Diagnosing COVID-19: the disease and tools for detection. ACS Nano. 2020;14:3822-3835.
Not in our library10.1021/acsnano.0c02624
105.
Draz MS, Shafiee H. Applications of gold nanoparticles in virus detection. Theranostics. 2018;8:1985-2017.
Not in our library10.7150/thno.23856
106.
Chen L, Liang J. An overview of functional nanoparticles as novel emerging antiviral therapeutic agents. Mater Sci Eng C. 2020;112:110924.
Not in our library10.1016/j.msec.2020.110924
107.
Cheng X, Chen G, Rodriguez WR. Micro- and nanotechnology for viral detection. Anal Bioanal Chem. 2009;393:487-501.
Not in our library10.1007/s00216-008-2514-x
108.
Waris A, Ali M, Khan AU, Ali A, Baset A. Exploring pathophysiology of COVID-19 infection: faux espoir and dormant therapeutic options. Int J Clin Virol. 2020;4:065-070.
Not in our library
109.
Moitra P, Alafeef M, Dighe K, Frieman MB, Pan D. Selective naked-eye detection of SARS-CoV-2 mediated by N gene targeted antisense oligonucleotide capped plasmonic nanoparticles. ACS Nano. 2020;14:7617-7627.
Not in our library10.1021/acsnano.0c03822
110.
Halfpenny KC, Wright DW. Nanoparticle detection of respiratory infection: nanoparticle detection of respiratory infection. WIREs Nanomed Nanobiotechnol. 2010;2:277-290.
Not in our library10.1002/wnan.83
111.
Talebian S, Wallace GG, Schroeder A, Stellacci F, Conde J. Nanotechnology-based disinfectants and sensors for SARS-CoV-2. Nat Nanotechnol. 2020;15:618-621.
Not in our library10.1038/s41565-020-0751-0
112.
Layqah LA, Eissa S. An electrochemical immunosensor for the corona virus associated with the Middle East respiratory syndrome using an array of gold nanoparticle-modified carbon electrodes. Microchim Acta. 2019;186:224.
Not in our library10.1007/s00604-019-3345-5
113.
Kim H, Park M, Hwang J, Kim JH, Chung D-R, Lee K, et al. Development of label-free colorimetric assay for MERS-CoV using gold nanoparticles. ACS Sens. 2019;4:1306-1312.
Not in our library10.1021/acssensors.9b00175
114.
Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosis · 2020
No notice
115.
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR · 2020
Expression of concern
116.
Zhao Z, Cui H, Song W, Ru X, Zhou W, Yu X. A simple magnetic nanoparticles-based viral RNA extraction method for efficient detection of SARS-CoV-2. Mol Biol. 2020.
Not in our library10.1101/2020.02.22.961268
117.
Brazilchuck N. From thousands of tiny magnetic balls to 150,000 COVID-19 tests per week. Norwegian SciTech News. 2020. https://norwegianscitechnews.com/2020/04/from-thousands-of-tiny-magnetic-balls-to-150000-covid-19-tests-per-week/. Accessed 10 Aug 2020.
Not in our library
118.
Seo G, Lee G, Kim MJ, Baek S-H, Choi M, Ku KB, et al. Rapid detection of COVID-19 causative virus (SARS-CoV-2) in Human nasopharyngeal swab specimens using field-effect transistor-based biosensor. ACS Nano. 2020;14:5135-5142.
Not in our library10.1021/acsnano.0c02823
119.
Santiago I. Trends and innovations in biosensors for COVID-19 mass testing. ChemBioChem. 2020.
Not in our library10.1002/cbic.202000250
120.
Nguyen TM, Zhang Y, Pandolfi PP. Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses. Cell Res. 2020;30:189-190.
Not in our library10.1038/s41422-020-0290-0
121.
Solaimuthu A, Vijayan AN, Murali P, Korrapati PS. Nano-biosensors and their relevance in tissue engineering. Curr Opin Biomed Eng. 2020;13:84-93.
Not in our library
122.
Zhu X, Wang X, Han L, Chen T, Wang L, Li H, et al. Reverse transcription loop-mediated isothermal amplification combined with nanoparticles-based biosensor for diagnosis of COVID-19. 2020. 10.1101/2020.03.17.20037796.
Not in our library10.1016/j.bios.2020.112437
123.
Chen Z, Zhang Z, Zhai X, Li Y, Lin L, Zhao H, et al. Rapid and Sensitive detection of anti-SARS-CoV-2 IgG, using lanthanide-doped nanoparticles-based lateral flow immunoassay. Anal Chem. 2020;92:7226-7231.
Not in our library10.1021/acs.analchem.0c00784
124.
Qiu G, Gai Z, Tao Y, Schmitt J, Kullak-Ublick GA, Wang J. Dual-functional plasmonic photothermal biosensors for highly accurate severe acute respiratory syndrome coronavirus 2 detection. ACS Nano. 2020;14:5268-5277.
Not in our library10.1021/acsnano.0c02439
125.
Somvanshi SB, Kharat PB, Saraf TS, Somwanshi SB, Shejul SB, Jadhav KM. Multifunctional nano-magnetic particles assisted viral RNA-extraction protocol for potential detection of COVID-19. Mater Res Innov. 2020;24:1-6.
Not in our library
126.
Wang M, Fu A, Hu B, Tong Y, Liu R, Liu Z, et al. Nanopore targeted sequencing for the accurate and comprehensive detection of SARS-CoV-2 and other respiratory viruses. Small. 2020;16(32):2002169.
Not in our library10.1002/smll.202002169
127.
Huang L, Ding L, Zhou J, Chen S, Chen F, Zhao C, et al. One-step rapid quantification of SARS-CoV-2 virus particles via low-cost nanoplasmonic sensors in generic microplate reader and point-of-care device. BioRxiv. 2020;142373:1-18.
Not in our library10.1016/j.bios.2020.112685
128.
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323(18):1824-1836.
Not in our library10.1001/jama.2020.6019
129.
Salvi R, Patankar P. Emerging pharmacotherapies for COVID-19. Biomed Pharmacother. 2020;128:110267.
Not in our library10.1016/j.biopha.2020.110267
130.
García-Serradilla M, Risco C, Pacheco B. Drug repurposing for new, efficient, broad spectrum antivirals. Virus Res. 2019;264:22-31.
Not in our library10.1016/j.virusres.2019.02.011
131.
Targeting Cell Entry of Enveloped Viruses as an Antiviral Strategy · 2010
Not checked
132.
The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus · 2020
No notice
133.
Discovery and development of safe-in-man broad-spectrum antiviral agents · 2020
No notice
134.
The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro · 2020
No notice
135.
Clercq ED, Li G. approved antiviral drugs over the past 50 years. Clin Microbiol Rev. 2016;29:695-747.
Not in our library10.1128/cmr.00102-15
136.
Al-Bari MAA. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother. 2015;70:1608-1621.
Not in our library10.1093/jac/dkv018
137.
Thomas E, Ghany MG, Liang TJ. The application and mechanism of action of ribavirin in therapy of hepatitis C. Antivir Chem Chemother. 2012;23:1-12.
Not in our library10.3851/imp2125
138.
Sofias AM, Andreassen T, Hak S. Nanoparticle ligand-decoration procedures affect in vivo interactions with immune cells. Mol Pharm. 2018;15:5754-5761.
Not in our library10.1021/acs.molpharmaceut.8b00908
139.
Sun X, Wang T, Cai D, Hu Z, Chen J, Liao H, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020;53:38-42.
Not in our library10.1016/j.cytogfr.2020.04.002
140.
Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 2020;80:607-613.
Not in our library10.1016/j.jinf.2020.03.037
141.
Leuschner F, Dutta P, Gorbatov R, Novobrantseva TI, Donahoe JS, Courties G, et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol. 2011;29:1005-1010.
Not in our library10.1038/nbt.1989
142.
Testori A. The “perfect cytokine storm” of covID-19. Mayo Clin Proc. 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256537/.
Not in our library10.1016/j.mayocp.2020.05.015
143.
Khalvati B, Sheikhsaran F, Sharifzadeh S, Kalantari T, Behzad Behbahani A, Jamshidzadeh A, et al. Delivery of plasmid encoding interleukin-12 gene into hepatocytes by conjugated polyethylenimine-based nanoparticles. Artif Cells Nanomed Biotechnol. 2017;45:1036-1044.
Not in our library10.1080/21691401.2016.1202256
144.
Zeng L, Ma W, Shi L, Chen X, Wu R, Zhang Y, et al. Poly(lactic-co-glycolic acid) nanoparticle-mediated interleukin-12 delivery for the treatment of diabetic retinopathy. IJN. 2019;14:6357-6369.
Not in our library10.2147/ijn.s214727
145.
Gao H, Xiong Y, Zhang S, Yang Z, Cao S, Jiang X. RGD and interleukin-13 peptide functionalized nanoparticles for enhanced glioblastoma cells and neovasculature dual targeting delivery and elevated tumor penetration. Mol Pharm. 2014;11:1042-1052.
Not in our library10.1021/mp400751g
146.
Prolonged Release and Functionality of Interleukin-10 Encapsulated within PLA-PEG Nanoparticles · 2019
Not checked
147.
Dormont F, Brusini R, Cailleau C, Reynaud F, Peramo A, Gendron A, et al. Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents. Sci Adv. 2020;6:eaaz5466.
Not in our library10.1126/sciadv.aaz5466
148.
Loutfy SA, Elberry MH, Farroh KY, Mohamed HT, Mohamed AA, Mohamed EB, et al. Antiviral activity of chitosan nanoparticles encapsulating curcumin against hepatitis C virus genotype 4a in human hepatoma cell lines. IJN. 2020;15:2699-2715.
Not in our library10.2147/ijn.s241702
149.
Dey P, Bergmann T, Cuellar-Camacho JL, Ehrmann S, Chowdhury MS, Zhang M, et al. Multivalent flexible nanogels exhibit broad-spectrum antiviral activity by blocking virus entry. ACS Nano. 2018;12:6429-6442.
Not in our library10.1021/acsnano.8b01616
150.
Hendricks GL, Weirich KL, Viswanathan K, Li J, Shriver ZH, Ashour J, et al. Sialylneolacto-N-tetraose c (LSTc)-bearing liposomal decoys capture influenza A virus. J Biol Chem. 2013;288:8061-8073.
Not in our library10.1074/jbc.m112.437202
151.
Łoczechin A, Séron K, Barras A, Giovanelli E, Belouzard S, Chen Y-T, et al. Functional carbon quantum dots as medical countermeasures to human coronavirus. ACS Appl Mater Interfaces. 2019;11:42964-42974.
Not in our library10.1021/acsami.9b15032
152.
Hu C-MJ, Chen Y-T, Fang Z-S, Chang W-S, Chen H-W. Antiviral efficacy of nanoparticulate vacuolar ATPase inhibitors against influenza virus infection. Int J Nanomed. 2018;13:8579-8593.
Not in our library10.2147/ijn.s185806
153.
Abbott TR, Dhamdhere G, Liu Y, Lin X, Goudy L, Zeng L, et al. Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza. Cell. 2020;181(865–876):e12.
Not in our library10.1016/j.cell.2020.04.020
154.
Baram-Pinto D, Shukla S, Gedanken A, Sarid R. Inhibition of HSV-1 attachment, entry, and cell-to-cell spread by functionalized multivalent gold nanoparticles. Small. 2010;6:1044-1050.
Not in our library10.1002/smll.200902384
155.
Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2 · 2020
No notice
156.
Cagno V, Andreozzi P, D’Alicarnasso M, Jacob Silva P, Mueller M, Galloux M, et al. Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism. Nat Mater. 2018;17:195-203.
Not in our library10.1038/nmat5053
157.
Jones ST, Cagno V, Janeček M, Ortiz D, Gasilova N, Piret J, et al. Modified cyclodextrins as broad-spectrum antivirals. Sci Adv. 2020;6:eaax9318.
Not in our library10.1126/sciadv.aax9318
158.
Wu C-J, Huang H-W, Liu C-Y, Hong C-F, Chan Y-L. Inhibition of SARS-CoV replication by siRNA. Antiviral Res. 2005;65:45-48.
Not in our library10.1016/j.antiviral.2004.09.005
159.
Li T, Zhang Y, Fu L, Yu C, Li X, Li Y, et al. siRNA targeting the Leader sequence of SARS-CoV inhibits virus replication. Gene Ther. 2005;12:751-761.
Not in our library10.1038/sj.gt.3302479
160.
Rabaan AA, Al-Ahmed SH, Haque S, Sah R, Tiwari R, Malik YS, et al. SARS-CoV-2, SARS-CoV, and MERS-COV: a comparative overview. Infez Med. 2020;28:174-184.
Not in our library
161.
Ceccarelli M, Berretta M, Venanzi Rullo E, Nunnari G, Cacopardo B. Differences and similarities between Severe Acute Respiratory Syndrome (SARS)-CoronaVirus (CoV) and SARS-CoV-2. Would a rose by another name smell as sweet? Eur Rev Med Pharmacol Sci. 2020;24:2781-2783.
Not in our library10.26355/eurrev_202003_20551
162.
Ghosh S, Firdous SM, Nath A. siRNA could be a potential therapy for COVID-19. EXCLI J. 2020;19:528-531.
Not in our library10.17179/excli2020-1328
163.
Levanova A, Poranen MM. RNA interference as a prospective tool for the control of human viral infections. Front Microbiol. 2018;9:2151.
Not in our library10.3389/fmicb.2018.02151
164.
Rohiwal SS, Dvorakova N, Klima J, Vaskovicova M, Senigl F, Slouf M, et al. Polyethylenimine based magnetic nanoparticles mediated non-viral CRISPR/Cas9 system for genome editing. Sci Rep. 2020;10:4619.
Not in our library10.1038/s41598-020-61465-6
165.
The promise and challenge of therapeutic genome editing · 2020
No notice
166.
Tanaka P, Santos J, Oliveira E, Miglioli N, Assis A, Monteleone-Cassiano A, et al. A Crispr-Cas9 system designed to introduce point mutations into the human ACE2 gene to weaken the interaction of the ACE2 receptor with the SARS-CoV-2 S protein. Preprints; 2020. https://www.preprints.org/manuscript/202005.0134/v1. Accessed 19 June 2020.
Not in our library
167.
Deng H, Huang W, Zhang Z. Nanotechnology based CRISPR/Cas9 system delivery for genome editing: progress and prospect. Nano Res. 2019;12:2437-2450.
Not in our library
168.
Aghamiri S, Talaei S, Ghavidel AA, Zandsalimi F, Masoumi S, Hafshejani NH, et al. Nanoparticles-mediated CRISPR/Cas9 delivery: recent advances in cancer treatment. J Drug Deliv Sci Technol. 2020;56:101533.
Not in our library
169.
Glass Z, Li Y, Xu Q. Nanoparticles for CRISPR–Cas9 delivery. Nat Biomed Eng. 2017;1:854-855.
Not in our library10.1038/s41551-017-0158-x
170.
Lee K, Conboy M, Park HM, Jiang F, Kim HJ, Dewitt MA, et al. Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair. Nat Biomed Eng. 2017;1:889-901.
Not in our library10.1038/s41551-017-0137-2
171.
Chen F, Alphonse M, Liu Q. Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics. WIREs Nanomed Nanobiotechnol. 2020;12:e1609.
Not in our library10.1002/wnan.1609
172.
Liu J, Chang J, Jiang Y, Meng X, Sun T, Mao L, et al. Fast and efficient CRISPR/Cas9 genome editing in vivo enabled by bioreducible lipid and messenger RNA nanoparticles. Adv Mater. 2019;31:1902575.
Not in our library10.1002/adma.201902575
173.
Moyer TJ, Zmolek AC, Irvine DJ. Beyond antigens and adjuvants: formulating future vaccines. J Clin Investig. 2016;126:799.
Not in our library10.1172/jci81083
174.
Sautto GA, Kirchenbaum GA, Diotti RA, Criscuolo E, Ferrara F. Next generation vaccines for infectious diseases. J Immunol Res. 2019;2019:5890962.
Not in our library10.1155/2019/5890962
175.
Lung P, Yang J, Li Q. Nanoparticle formulated vaccines: opportunities and challenges. Nanoscale. 2020;12:5746-5763.
Not in our library10.1039/c9nr08958f
176.
Kim S-H, Jang Y-S. The development of mucosal vaccines for both mucosal and systemic immune induction and the roles played by adjuvants. Clin Exp Vaccine Res. 2017;6:15.
Not in our library10.7774/cevr.2017.6.1.15
177.
A Comparison of Plasmid DNA and mRNA as Vaccine Technologies · 2019
No notice
178.
Kim CG, Kye Y-C, Yun C-H. The role of nanovaccine in cross-presentation of antigen-presenting cells for the activation of CD8+ T cell responses. Pharmaceutics. 2019;11:612.
Not in our library10.3390/pharmaceutics11110612
179.
Xiang SD, Scholzen A, Minigo G, David C, Apostolopoulos V, Mottram PL, et al. Pathogen recognition and development of particulate vaccines: does size matter? Methods. 2006;40:1-9.
Not in our library10.1016/j.ymeth.2006.05.016
180.
Shin MD, Shukla S, Chung YH, Beiss V, Chan SK, Ortega-Rivera OA, et al. COVID-19 vaccine development and a potential nanomaterial path forward. Nat Nanotechnol. 2020;15:646-655.
Not in our library10.1038/s41565-020-0737-y
181.
Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection · 2020
No notice
182.
Moon JJ, Suh H, Polhemus ME, Ockenhouse CF, Yadava A, Irvine DJ. Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine. PLoS ONE. 2012;7:e31472.
Not in our library10.1371/journal.pone.0031472
183.
Papadopoulos NG, Megremis S, Kitsioulis NA, Vangelatou O, West P, Xepapadaki P. Promising approaches for the treatment and prevention of viral respiratory illnesses. J Allergy Clin Immunol. 2017;140:921-932.
Not in our library10.1016/j.jaci.2017.07.001
184.
Gomes AC, Mohsen M, Bachmann MF. Harnessing nanoparticles for immunomodulation and vaccines. Vaccines. 2017;5:6.
Not in our library10.3390/vaccines5010006
185.
Angioletti-Uberti S. Theory, simulations and the design of functionalized nanoparticles for biomedical applications: a soft matter perspective. npj Comput Mater. 2017;3:48.
Not in our library
186.
Schneider CS, Xu Q, Boylan NJ, Chisholm J, Tang BC, Schuster BS, et al. Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation. Sci Adv. 2017;3:e1601556.
Not in our library10.1126/sciadv.1601556
187.
Lurie N, Saville M, Hatchett R, Halton J. Developing covid-19 Vaccines At Pandemic Speed. N Engl J Med. 2020;382:1969-1973.
Not in our library10.1056/nejmp2005630
188.
Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity. 2020;52:583-589.
Not in our library10.1016/j.immuni.2020.03.007
189.
Du L, He Y, Zhou Y, Liu S, Zheng B-J, Jiang S. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7:226-236.
Not in our library10.1038/nrmicro2090
190.
COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning · 2020
No notice
191.
EpiVax. EPV-CoV19: HCW vaccine. EpiVax, Inc.—Informatics and Immunology. 2020. https://epivax.com/pipeline/epv-cov19. Accessed 16 June 2020.
Not in our library
192.
Magnusson SE, Altenburg AF, Bengtsson KL, Bosman F, de Vries RD, Rimmelzwaan GF, et al. Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice. Immunol Res. 2018;66:224-233.
Not in our library10.1007/s12026-018-8991-x
193.
Novavax. Novavax to receive up to $388 million funding from CEPI for COVID-19 vaccine development and manufacturing | Novavax Inc. - IR Site. 2020. http://ir.novavax.com/news-releases/news-release-details/novavax-receive-388-million-funding-cepi-covid-19-vaccine. Accessed 16 June 2020.
Not in our library
194.
Advances in mRNA Vaccines for Infectious Diseases · 2019
No notice
195.
Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261-279.
Not in our library10.1038/nrd.2017.243
196.
WHO. Draft landscape of COVID-19 candidate vaccines. 2020. https://www.who.int/who-documents-detail-redirect/draft-landscape-of-covid-19-candidate-vaccines. Accessed 13 June 2020.
Not in our library
197.
Sportelli MC, Picca RA, Cioffi N. Recent advances in the synthesis and characterization of nano-antimicrobials. Trends Anal Chem. 2016;84:131-138.
Not in our library
198.
Gunell M, Haapanen J, Brobbey KJ, Saarinen JJ, Toivakka M, Mäkelä JM, et al. Antimicrobial characterization of silver nanoparticle-coated surfaces by “touch test” method. Nanotechnol Sci Appl. 2017;10:137-145.
Not in our library10.2147/nsa.s139505
199.
Swaminathan M, Sharma NK. Antimicrobial Activity of the engineered nanoparticles used as coating agents. In: Martínez LMT, Kharissova OV, Kharisov BI, editors. Handbook of ecomaterials. Cham: Springer International Publishing; 2019. p. 549–63. 10.1007/978-3-319-68255-6_1. Accessed 28 Apr 2020.
Not in our library
200.
Mitchell SL, Carlson EE. Tiny things with enormous impact: nanotechnology in the fight against infectious disease. ACS Infect Dis. 2018;4:1432-1435.
Not in our library10.1021/acsinfecdis.8b00138
201.
Polyak B, Cordovez B. How can we predict behavior of nanoparticles in vivo ? Nanomedicine. 2016;11:189-192.
Not in our library10.2217/nnm.15.192
202.
Alternative Antimicrobial Approach: Nano-Antimicrobial Materials · 2015
No notice
203.
Wacker MG, Proykova A, Santos GML. Dealing with nanosafety around the globe-regulation vs. innovation. Int J Pharm. 2016;509:95-106.
Not in our library10.1016/j.ijpharm.2016.05.015
204.
Ventola CL. Progress in nanomedicine: approved and investigational nanodrugs. Pharm Ther. 2017;42:742-755.
Not in our library
205.
Caster JM, Patel AN, Zhang T, Wang A. Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;9:e1416.
Not in our library10.1002/wnan.1416
206.
Zhdanov VP. Formation of a protein corona around nanoparticles. Curr Opin Colloid Interface Sci. 2019;41:95-103.
Not in our library
207.
Lane LA, Qian X, Smith AM, Nie S. Physical chemistry of nanomedicine: understanding the complex behaviors of nanoparticles in vivo. Annu Rev Phys Chem. 2015;66:521-547.
Not in our library10.1146/annurev-physchem-040513-103718
208.
Berrecoso G, Crecente-Campo J, Alonso MJ. Unveiling the pitfalls of the protein corona of polymeric drug nanocarriers. Drug Deliv Transl Res. 2020;10:730-750.
Not in our library10.1007/s13346-020-00745-0

Cited by papers we hold 4

Nanoparticles: Taking a Unique Position in Medicine · 2023
No notice
Unique Properties of Surface-Functionalized Nanoparticles for Bio-Application: Functionalization Mechanisms and Importance in Application · 2022
No notice
Synergistic Effects Between Metal Nanoparticles and Commercial Antimicrobial Agents: A Review · 2022
No notice
Comprehensive and comparative studies on nanocytotoxicity of glyceryl monooleate- and phytantriol-based lipid liquid crystalline nanoparticles · 2021
Not checked

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.